- Professor of Pharmacology at the University of Oxford
- Pro to the question "Should Marijuana Be a Medical Option?"
“The available animal data are more than adequate to justify its approval as a human medicine.”
“Cannabis Less Harmful Than Aspirin, Says Scientist,” Independent (UK), Oct. 20, 2000
- Theoretical Expertise Ranking:
Individuals with MDs, PhDs, JDs, or equivalent advanced degrees in fields relevant to medical marijuana. Also top-level government officials (such as foreign leaders, US presidents, Founding Fathers, Supreme Court Justices, members of legislative bodies, cabinet members, military leaders, etc.) with positions relevant to medical marijuana issues.
- Involvement and Affiliations:
- Professor, Department of Pharmacology, University of Oxford
- Chairman of the Board/Director, ACADIA Pharmaceuticals, Incorporated, 2000-present
- Founder and Director, Panos Therapeutics Ltd.
- Director, Wolfson Centre for Research on Age-Related Diseases,Kings College London, 1999-2004
- Director, Neuroscience Research Centre Merck Research Laboratories, 1983-1995
- Director, UK Medical Research Council Neurochemical Pharmacology Unit, 1970-1983
- Fellow of the Royal Society of London
- Foreign Associate of the National Academy of Sciences, USA
- PhD, University of Cambridge
- BA, University of Cambridge
- Acted as the specialist adviser to the House of Lords Science & Technology Committee’s inquiry into Cannabis, 1998
- Quoted in: